Citation: ; Expert Review of Cardiovascular Therapy. 18(5):261-267, 2020 May..Journal: Expert review of cardiovascular therapy.Published: ; 2020; ; ISSN: 1477-9072.Full author list: Garcia-Garcia HM; Mintz GS; Ozaki Y; Waksman R.UI/PMID: 32321328.Subject(s): Coronary Artery Disease/th [Therapy] | Treatment Outcome | *Tomography, Optical Coherence/mt [Methods] | Thrombosis/et [Etiology] | *Platelet Aggregation Inhibitors/ad [Administration & Dosage] | Neointima | Humans | Hemorrhage/ci [Chemically Induced] | *Drug-Eluting StentsInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: https://dx.doi.org/10.1080/14779072.2020.1759421 (Click here)Abbreviated citation: ; Expert Rev Cardiovasc Ther. 18(5):261-267, 2020 May.Abstract: Introduction: Dual antiplatelet therapy (DAPT) is required for coronary artery disease treated with drug-eluting stents (DES) implantation. Shortening DAPT duration would be beneficial for patients with high bleeding risk. Areas covered: Early healing patterns, especially stent strut coverage, assessed by optical coherence tomography (OCT) as a surrogate of neointima have been investigated to make decisions on whether short DAPT would be a safe alternative. This review evaluates the OCT evidence (i.e. neointimal coverage of stent struts within 3 months) for shortening DAPT duration after DES implantation. Expert commentary: Shortening DAPT (i.e. within 3 months) duration after DES implantation might reduce complications including bleeding without increasing stent thrombosis. However, the optimal duration of DAPT after DES implantation is under discussion. Long-term assessment of short DAPT is required for the decision of the new guidelines regarding the recommended duration of DAPT.